Teprotumumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Teprotumumab and local guidelines before prescribing.
IGF-1R antibody
Mechanism
IGF-1 receptor monoclonal antibody.
Uses
Thyroid eye disease.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Hearing loss, hyperglycaemia, muscle spasms.
Interactions
Few.
Contraindications and cautions
Pregnancy
Monitoring
Hearing, glucose
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Baseline audiology and glucose.
More from the textbook: uses, cautions and other points
- Teprotumumab (anti-IGF-1 receptor antibody) - MHRA-approved for moderate to severe disease; NICE appraisal not yet complete. Side effects: hearing loss, high glucose.
Ophthalmology: Neuro-ophthalmology - Thyroid eye disease — stop smoking, achieve euthyroid state, selenium (mild), IV methylprednisolone (active moderate–severe), mycophenolate, orbital radiotherapy, decompression; teprotumumab (IGF-1R antibody — check UK availability).
Ophthalmology: Anatomy Physiology and Pharmacology - Teprotumumab | Anti-IGF-1R antibody for moderate to severe thyroid eye disease; hearing loss, high glucose.
Ophthalmology: Neuro-ophthalmology
Where it is discussed in the book
- Ophthalmology: Anatomy Physiology and Pharmacology (1 mention)
- Ophthalmology: Neuro-ophthalmology (2 mentions)
- Ophthalmology: Paediatrics (1 mention)